Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

1.36
-0.0600-4.23%
Post-market: 1.360.00000.00%19:43 EDT
Volume:36.80K
Turnover:49.97K
Market Cap:4.17M
PE:-0.15
High:1.45
Open:1.45
Low:1.33
Close:1.42
Loading ...

Sonnet Releases Virtual Investor "What This Means" Segment

GlobeNewswire
·
16 Apr

Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
07 Apr

Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up

MT Newswires Live
·
05 Apr

Sonnet Biotherapeutics Holdings Inc trading resumes

TIPRANKS
·
04 Apr

Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo

TIPRANKS
·
04 Apr

BRIEF-Sonnet’S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer

Reuters
·
04 Apr

Sonnet Biotherapeutics Holdings Inc - Topline Safety Data Suggest Clinical Benefit of Son-1010 With Atezolizumab

THOMSON REUTERS
·
04 Apr

Sonnet’s Son-1010 Demonstrates a Strong Safety Profile in Combination With Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

THOMSON REUTERS
·
04 Apr

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

GlobeNewswire
·
04 Apr

Sonnet Biotherapeutics Holdings Inc trading halted, news pending

TIPRANKS
·
04 Apr

Sonnet Announces Release of Corporate Update Video

GlobeNewswire
·
02 Apr

BRIEF-Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan

Reuters
·
01 Apr

Sonnet Biotherapeutics Holdings - Board Has Unanimously Approved Appointment of Raghu Rao as Interim CEO

THOMSON REUTERS
·
01 Apr

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.d.

THOMSON REUTERS
·
01 Apr

Press Release: Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Dow Jones
·
01 Apr

Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
28 Mar

BRIEF-Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas

Reuters
·
26 Mar

Sonnet Biotherapeutics Successfully Completes First Safety Review of Son-1010 in Combination With Trabectedin in Certain Sarcomas

THOMSON REUTERS
·
26 Mar

Sonnet Biotherapeutics Holdings : Safety Review Committee Found No Unexpected Toxicities in Early Dosing of Son-1010 in First 7 Patients at Mtd

THOMSON REUTERS
·
26 Mar

Sonnet Biotherapeutics : Annual Review Showed Extended Safety of Son-1010 Monotherapy at Mtd With Clinical Benefit in 83% of Patients at That Dose

THOMSON REUTERS
·
26 Mar